title: Tailored surgical therapy for acute native mitral valve endocarditis.
abstract: OBJECTIVE
  Mitral valve repair has been shown superior to valve replacement for the treatment of non-infectious valve disease. The criteria and results of valve repair for native valve endocarditis are still being defined. The study aim was to examine the short- and long-term results of mitral valve repair and replacement for acute infective endocarditis and to define criteria for the use of each technique.
  
  
  METHODS
  A total of 53 consecutive patients who presented with acute native mitral valve infective endocarditis (diagnosed less than six weeks before surgery) between January 1992 and June 2002 was retrospectively analyzed.
  
  
  RESULTS
  Twenty-one patients (40%) underwent mitral valve repair, and 32 (60%) underwent valve replacement. Operative mortality was 0% for the repair group and 13% (4/32) for the replacement group (p = 0.14). Median follow up was 4 years (range: 6-108 months). At five years follow up, a median ejection fraction (EF) of 60% and mitral regurgitation (MR) grade of 1/4 was observed, with an overall late survival of 85% (19/21), in the repair group, while the replacement group had a median EF of 55% and an overall late survival of 73% (p = 0.73). Recurrent endocarditis occurred in 2/21 (10%) in the repair group and 1/32 (3%) in the replacement group (p = 0.34).
  
  
  CONCLUSIONS
  Mitral valve repair is a safe and effective technique to treat acute native mitral valve infective endocarditis with favorable short- and long-term morbidity and mortality. Patients with advanced endocarditis and annular destruction require valve replacement. Mitral valve repair should be performed when technically feasible.
authors.affiliation: Division of Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: Tomislav
authors.initials: T
authors.lastname: Mihaljevic
authors.forename: Subroto
authors.initials: S
authors.lastname: Paul
authors.forename: Marzia
authors.initials: M
authors.lastname: Leacche
authors.forename: James D
authors.initials: JD
authors.lastname: Rawn
authors.forename: Sary
authors.initials: S
authors.lastname: Aranki
authors.forename: Patrick T
authors.initials: PT
authors.lastname: O'Gara
authors.forename: Lawrence H
authors.initials: LH
authors.lastname: Cohn
authors.forename: John G
authors.initials: JG
authors.lastname: Byrne
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004452:Echocardiography; D017548:Echocardiography, Transesophageal; D004697:Endocarditis, Bacterial / Q000382:microbiology* / Q000401:mortality / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000382:microbiology* / Q000401:mortality / Q000601:surgery*; D019918:Heart Valve Prosthesis Implantation / Q000401:mortality; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000000981:diagnostic imaging / Q000382:microbiology* / Q000601:surgery*; D011183:Postoperative Complications / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D012008:Recurrence; D012086:Reoperation; D013203:Staphylococcal Infections / Q000382:microbiology* / Q000401:mortality / Q000601:surgery*; D013223:Statistics as Topic; D013290:Streptococcal Infections / Q000382:microbiology* / Q000401:mortality / Q000601:surgery*; D013318:Stroke Volume / Q000502:physiology; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome